THE DEFINITIVE GUIDE TO HEMGENIX

Quantity of eligible individuals: CDEC mentioned the uncertainty in the amount of individuals with moderately extreme to extreme hemophilia B in Canada qualified for etranacogene dezaparvovec. Clinical specialists consulted by CADTH indicated that some patients who will be categorised as acquiring delicate or reasonable illness might have a serious